Angelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA Therapeutics for Epilepsy and other Neurological Disorders

• Angelini Ventures co-leads alongside Invivo Partners with participation from Innovestor’s Life Science Fund and other existing investors   
• Financing will support clinical development of Neumirna‘s lead asset NMT.001, a potential disease-modifying Antisense Oligonucleotide (ASO) therapy for drug-resistant epilepsy, as well as expand its R&D capabilities and scale its pioneering drug discovery platform
• Angelini Venture’s investment in Neumirna marks its 5th in the field of neurological disorders and represents a significant opportunity to support this critical therapeutic area with high growth potential

Rome, Italy, 8 January 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions and ideas in BioTech and Digital Health, today announces that it has co-led a €20 million Series A financing round in Neumirna Therapeutics, an RNA-focused biotech company developing next-generation therapeutics for neurological disorders.

Neumirna was founded in 2020 by Dr. Henrik Klitgaard, Prof. Sakari Kauppinen and Lars Hellerung Christiansen, with the mission to revolutionize and provide new treatment paradigms for challenging neurological conditions by harnessing the power of microRNAs (miRNAs) to provide disease-modifying drugs. The company's pioneering drug development platform enables the development of RNA therapies targeting previously intractable conditions, such as drug-resistant epilepsy (DRE) and Parkinson’s disease.

The proceeds of the Series A financing will enable Neumirna to advance its lead asset NMT.001 for the treatment of epilepsy into clinical development bringing NMT.001 towards clinical validation. Proceeds will also expand its R&D capabilities and scale its pioneering platform.

Angelini Ventures selected Neumirna in line with its investment strategy of supporting and advancing the most promising life sciences companies. As Angelini Ventures’ 5th investment in a neuroscience-focused company, Neumirna’s novel approach and cutting-edge technology shows significant potential for developing effective therapies for patients with neurological disorders.

Thomas Thestrup, Senior Principal at Angelini Ventures, said: “As co-lead investors, we are proud to support Neumirna in its mission to harness the potential of RNA therapies to tackle epilepsy and other complex neurological disorders. By leveraging microRNA-targeted drugs to address the underlying causes of diseases like epilepsy and Parkinson’s disease, Neumirna is breaking new ground in the field. With our strong focus on brain disorders and a commitment to advancing innovative treatments for epilepsy, we are excited to collaborate with Neumirna’s management team on this journey to develop transformative solutions for patients worldwide.”

Professor Janine Erler, CEO of Neumirna Therapeutics, commented: “This funding milestone is a testament to the groundbreaking potential of our RNA-based platform and our lead development candidate, NMT.001. We are thrilled to have the support of leading international investors, who share our vision of addressing the unmet needs of patients living with neurological disorders. This funding is essential to bring NMT.001 to clinical trials and advance our pipeline.”